Browsing Category
Pharma Industry News
4720 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Can Coartem Baby reshape treatment standards for newborn malaria patients?
Can Coartem Baby reshape neonatal malaria care? Explore what Novartis Pharma AG’s WHO milestone means for global health access and strategy.
How Levicept Ltd. is advancing neurotrophin-3 inhibition in osteoarthritis treatment
Levicept Ltd.’s LEVI-04 Phase II data could reshape osteoarthritis treatment. Discover what this means for investors, regulators, and drug pipelines.
Sun Pharmaceutical (NSE: SUNPHARMA) bets $11.75bn on Organon (NYSE: OGN) to become a top global pharma player
Sun Pharma is borrowing scale to escape the generics trap. Organon could reshape its global pharma identity if execution holds.
Paradigm Biopharmaceuticals (ASX: PAR) raises A$14m as Phase 3 osteoarthritis trial enters decisive window
Paradigm Biopharmaceuticals has more cash, but Zilosul still needs Phase 3 proof. ASX:PAR now turns from funding risk to data risk.
What manufacturing scale-up means for REYOBIQ’s regulatory and clinical trajectory
Explore how Plus Therapeutics Inc. is scaling REYOBIQ manufacturing and what it means for regulatory approval and clinical success.
Can Moleculin Biotech, Inc. translate preclinical pancreatic cancer signals into clinical impact?
Explore how Plus Therapeutics Inc. is scaling REYOBIQ manufacturing and what it means for regulatory approval and clinical success.
What clinicians and regulators will watch next after Itvisma’s positive CHMP opinion
Novartis Pharma AG’s Itvisma gains CHMP backing. Discover what clinicians, regulators, and investors will watch next in SMA gene therapy.
How oral Targeted Glue degraders could change dosing paradigms in cancer treatment
Discover how oral Targeted Glue degraders could transform cancer dosing strategies and reshape oncology treatment models. Read the full analysis.
Merck’s $6.7bn Terns deal moves closer as TERN trades near offer price
Merck cleared a deal hurdle. TERN-701 now has to show whether one CML asset can justify a $6.7bn oncology bet.
What NPX-5’s Phase IIb trial means for the future of oncology-linked mental health treatments
NPX-5 enters Phase IIb trials for cancer-related mental health. Discover what this means for biotech strategy, regulation, and future treatments.